Comparative Pharmacology
Head-to-head clinical analysis: IMITREX versus IMITREX STATDOSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IMITREX versus IMITREX STATDOSE.
IMITREX vs IMITREX STATDOSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin 5-HT1B/1D receptor agonist; causes vasoconstriction of cranial blood vessels and inhibits release of pro-inflammatory neuropeptides.
Selective agonist at serotonin 5-HT1B/1D receptors, causing vasoconstriction of cranial blood vessels and inhibition of trigeminal nerve transmission.
50 mg to 100 mg orally at onset of migraine; may repeat after 2 hours if needed, max 200 mg/day. Alternatively, 6 mg subcutaneously once, may repeat after 1 hour, max 12 mg/day. Intranasal: 5 mg to 20 mg in one nostril at onset; may repeat after 2 hours, max 40 mg/day.
6 mg subcutaneously once, may repeat after 1 hour if needed; maximum 12 mg in 24 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 2.5 hours (range 2–3 hours). This short half-life supports its use for acute migraine attacks but may require repeat dosing for prolonged symptoms.
Terminal half-life ~2 hours; clinical context: no significant accumulation with repeated dosing.
Primarily renal excretion of unchanged drug and metabolites (approximately 80% of total clearance), with about 20% eliminated in feces via biliary excretion. About 40% of the dose is excreted unchanged in urine.
Approximately 60% renal, 40% fecal (via bile); <1% unchanged in urine.
Category C
Category C
Triptan
Triptan